---
schema_version: "secwatch.filing_event.v1"
accession: "0001411685-24-000042"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2024-09-23T23:59:59+00:00"
generated_at: "2026-05-31T02:21:31.860479+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vistagen enrolls first subject in PALISADE-4 Phase 3 trial of fasedienol for SAD

## Summary
- First subject enrolled in PALISADE-4 Phase 3 trial of fasedienol nasal spray for acute treatment of social anxiety disorder (SAD).
- Fasedienol is an investigational neuroactive pherine candidate in U.S. registration-directed Phase 3 development.
- Over 30 million Americans suffer from SAD; no FDA-approved acute treatments currently available.
- Fasedienol targets nose-to-brain neural circuits to reduce fear and anxiety associated with SAD.
- CEO Shawn Singh confirmed the milestone was achieved as planned in the registration-directed program.

## SEC filing metadata
- accession: 0001411685-24-000042
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2024-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000141168524000042/0001411685-24-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000141168524000042/vtgn-20240923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411685-24-000042
- JSON: https://secwatch.observer/filing/0001411685-24-000042.json
- Plain text: https://secwatch.observer/filing/0001411685-24-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.